Topics:
Rheumatology • Vasculitis • ANCA Vasculitis • Journal Club ft. NEJM publications • Dermatology
How should the results of the ADVOCATE trial be applied in AAV patients who receive rituximab induction and maintenance therapy?
In the ADVOCATE trial, patients were not re-dosed with rituximab.
Answer from: at Community Practice
The following answer was jointly drafted by Dr. Peter Merkel and Dr. David Jayne:The data from ADVOCATE indicate that patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) treated with avacopan 30 mg twice daily and prednisone placebo were able to achieve remission w...
Sign in or Register to read more